Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for REC-4881 in Cancer. The expected timing is based on the latest available company guidance and may change.
LILAC trial. 11/6/24- Safety and preliminary efficacy data in H1 2025. 5/5/25- No recent Q1'25 update. 11/05/25:- PR No update. 02/25/26:- Additional LILAC Ph1b/2 clinical data expected in H1 2027. 05/06/26:- Additional LILAC Ph1b/2 clinical data reiterated for H1 2027. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.